Focus: Ferring Pharmaceuticals is a small-molecule manufacturer headquartered in Buenos Aires with 5,000+ employees, specializing in urology, women's health, and gastroenterology. The company operates as a mature, established player with a portfolio of approved products generating $33M+ in annual Part D spending.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
Growing — net +14 jobs in 30d
70 jobs added vs 56 removed. Steady team buildout.
2 recent layoff filings (12 mo) — 128 affected
Source: state DOL filings via Big Local News
Ferring offers stable employment with an established product base but carries significant portfolio concentration risk requiring successful pipeline advancement for long-term career growth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product generating 91% of company revenue with patent protection extending to 2038, providing strong cash flow foundation.
Help build intelligence for Ferring Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ferring Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Smaller revenue contributor with patent life extending to 2032 in specialized oncology indication.
Peak-stage reproductive health product with patent protection through 2030, supporting women's health franchise.
Biologic product approaching loss of exclusivity with minimal current revenue, requiring pipeline transition planning.
24 discontinued, 9 duplicate formulations not shown
Novo's troubled Indiana plant claims another victim as FDA rejects Incyte's lung cancer application - Fierce Pharma
Novo's troubled Indiana plant claims another victim as FDA rejects Incyte's lung cancer application Fierce Pharma
Regulatory Affairs Job at Ferring Pharmaceuticals | Life Sciences Candidates, Apply Now - BioTecNika
Regulatory Affairs Job at Ferring Pharmaceuticals | Life Sciences Candidates, Apply Now BioTecNika
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy.
Feed injection-enabled reversed phase liquid chromatography for simplified analysis of lipophilic drugs and formulations.
+1 more products
Source: state DOL filings, aggregated via Big Local News
Active desmopressin shortage suggests manufacturing or supply chain challenges in small-molecule production, a core competency; operational risk warrants investigation during interview process.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo